Trials / Unknown
UnknownNCT04982939
Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
Efficacy and Safety of Peri-operative Sintilimab in Combination With SOX in Resectable Locally Advanced Gastric Cancer: a Multiple-center Open-label Randomized Phase II Trial.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 210 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate efficacy and safety of peri-operative sintilimab in combination with SOX in resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab | Sintilimab, 200mg IV d1 Q3W |
| DRUG | S-1 | S-1, 40-60mg BID d1-14 Q3W |
| DRUG | Oxaliplatin | Oxaliplatin，130mg/m2 d1 Q3W |
Timeline
- Start date
- 2021-06-21
- Primary completion
- 2023-06-21
- Completion
- 2024-06-21
- First posted
- 2021-07-29
- Last updated
- 2021-08-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04982939. Inclusion in this directory is not an endorsement.